n(g),n(g')-dimethyl-l-arginine has been researched along with Diabetic Angiopathies in 22 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of the meta-analysis was to evaluate the relationship between serum asymmetric dimethylarginine (ADMA) level and microvascular complications in diabetes mellitus (DM) including diabetic retinopathy (DR), diabetic neuropathy (DN), and diabetic nephropathy." | 9.01 | Relationship between Serum Asymmetric Dimethylarginine Level and Microvascular Complications in Diabetes Mellitus: A Meta-Analysis. ( Chen, W; He, K; Li, C; Liu, J; Ma, B; Ma, H; Tian, L; Zhao, P, 2019) |
| "Metformin, the drug of first choice in type 2 diabetes mellitus (T2DM), reduces cardiovascular (CV) morbidity and mortality in part independently of improved glycemic control and changes in traditional risk factors." | 6.80 | Differential associations of circulating asymmetric dimethylarginine and cell adhesion molecules with metformin use in patients with type 2 diabetes mellitus and stable coronary artery disease. ( Chyrchel, B; Golay, A; Kruszelnicka, O; Surdacki, A, 2015) |
| "Sixty-one young people with Type 1 diabetes without macrovascular disease or nephropathy and 62 healthy volunteers underwent brachial artery flow-mediated dilatation (FMD) and assay of plasma ADMA and adhesion molecules." | 5.35 | A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuria. ( Agarwal, SC; Böger, RH; Home, PD; Lüneburg, N; Schwedhelm, E; Sibal, L, 2009) |
| "The purpose of the meta-analysis was to evaluate the relationship between serum asymmetric dimethylarginine (ADMA) level and microvascular complications in diabetes mellitus (DM) including diabetic retinopathy (DR), diabetic neuropathy (DN), and diabetic nephropathy." | 5.01 | Relationship between Serum Asymmetric Dimethylarginine Level and Microvascular Complications in Diabetes Mellitus: A Meta-Analysis. ( Chen, W; He, K; Li, C; Liu, J; Ma, B; Ma, H; Tian, L; Zhao, P, 2019) |
| " However, it is unknown whether excess weight, insulin resistance, and asymmetric dimethylarginine (ADMA)--an endogenous nitric oxide (NO) synthase inhibitor--also contribute to the vascular changes observed in these patients." | 3.74 | Impaired vascular nitric oxide bioactivity in women with previous gestational diabetes. ( Kautzky-Willer, A; Langenberger, H; Mittermayer, F; Pacini, G; Pleiner, J; Schaller, G; Tura, A; Winzer, C; Wolzt, M, 2007) |
| "Patients with type 2 diabetes and diabetic microvascular complications have significantly elevated levels of Asymmetric dimethylarginine (ADMA), which is an endogenous inhibitor of nitric oxide synthase (NOS)." | 3.01 | Role of ADMA in the pathogenesis of microvascular complications in type 2 diabetes mellitus. ( Guo, X; Jin, W; Xing, Y, 2023) |
| "Metformin, the drug of first choice in type 2 diabetes mellitus (T2DM), reduces cardiovascular (CV) morbidity and mortality in part independently of improved glycemic control and changes in traditional risk factors." | 2.80 | Differential associations of circulating asymmetric dimethylarginine and cell adhesion molecules with metformin use in patients with type 2 diabetes mellitus and stable coronary artery disease. ( Chyrchel, B; Golay, A; Kruszelnicka, O; Surdacki, A, 2015) |
| " Indeed, endothelial dysfunction due to reduced synthesis and/or bioavailability of NO is thought to be an early step in the course of atherosclerotic cardiovascular disease (CVD)." | 2.44 | Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications. ( Matsui, T; Nakamura, K; Okuda, S; Ueda, S; Yamagishi, S, 2008) |
| "Patients with type 2 diabetes represent 50% of all sudden cardiac deaths." | 1.62 | Lack of evidence of the correlation between plasma Asymmetrical Dimethylarginine correlation and IMT in type 2 diabetic patients with chronic vascular complication. ( Adamiec, R; Dumas, I; Fiodorenko-Dumas, Z; Małecki, R; Paprocka-Borowicz, M; Rabczynski, M, 2021) |
| "Patients with type I diabetes mellitus (T1DM) have increased incidence of atherosclerosis and cardiovascular disease." | 1.46 | Osteoprotegerin, RANKL, ADMA, and Fetuin-A serum levels in children with type I diabetes mellitus. ( Chrysis, D; Efthymiadou, A; Kritikou, D; Mermigka, A; Spiliotis, BE, 2017) |
| "Seventy patients with type 2 diabetes mellitus and 11 healthy subjects were assessed concerning urine albumin: creatinine ratio, plasma and urinary advanced glycation end-products, plasma asymmetric dimethyl-arginine, serum cystatin C, intima-media thickness in the common carotid arteries, the pulsatility index, the resistance index in the internal carotid arteries and the middle cerebral arteries, the cerebrovascular reactivity through the breath-holding test." | 1.42 | Glycated peptides are associated with the variability of endothelial dysfunction in the cerebral vessels and the kidney in type 2 diabetes mellitus patients: a cross-sectional study. ( Bob, F; Dumitrascu, V; Gadalean, F; Gluhovschi, C; Gluhovschi, G; Jianu, DC; Petrica, L; Petrica, M; Popescu, R; Ursoniu, S; Velciov, S; Vlad, A; Vlad, D, 2015) |
| "Sixty-one young people with Type 1 diabetes without macrovascular disease or nephropathy and 62 healthy volunteers underwent brachial artery flow-mediated dilatation (FMD) and assay of plasma ADMA and adhesion molecules." | 1.35 | A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuria. ( Agarwal, SC; Böger, RH; Home, PD; Lüneburg, N; Schwedhelm, E; Sibal, L, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (36.36) | 29.6817 |
| 2010's | 12 (54.55) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, X | 1 |
| Xing, Y | 1 |
| Jin, W | 1 |
| Fiodorenko-Dumas, Z | 1 |
| Dumas, I | 1 |
| Rabczynski, M | 1 |
| Małecki, R | 1 |
| Adamiec, R | 1 |
| Paprocka-Borowicz, M | 1 |
| Liu, J | 1 |
| Li, C | 1 |
| Chen, W | 1 |
| He, K | 1 |
| Ma, H | 1 |
| Ma, B | 1 |
| Zhao, P | 1 |
| Tian, L | 1 |
| Anderssohn, M | 2 |
| McLachlan, S | 1 |
| Lüneburg, N | 3 |
| Robertson, C | 1 |
| Schwedhelm, E | 3 |
| Williamson, RM | 1 |
| Strachan, MW | 1 |
| Ajjan, R | 1 |
| Grant, PJ | 1 |
| Böger, RH | 3 |
| Price, JF | 1 |
| Celik, M | 1 |
| Cerrah, S | 1 |
| Arabul, M | 1 |
| Akalin, A | 1 |
| Petrica, L | 1 |
| Vlad, A | 1 |
| Gluhovschi, G | 1 |
| Gadalean, F | 1 |
| Dumitrascu, V | 1 |
| Vlad, D | 1 |
| Popescu, R | 1 |
| Velciov, S | 1 |
| Gluhovschi, C | 1 |
| Bob, F | 1 |
| Ursoniu, S | 1 |
| Petrica, M | 1 |
| Jianu, DC | 1 |
| Kruszelnicka, O | 1 |
| Chyrchel, B | 1 |
| Golay, A | 1 |
| Surdacki, A | 1 |
| Takaya, J | 1 |
| Tanabe, Y | 1 |
| Kuroyanagi, Y | 1 |
| Kaneko, K | 1 |
| Jing, Z | 1 |
| Kuang, L | 1 |
| Wang, Y | 1 |
| He, J | 1 |
| Sun, Z | 1 |
| Liu, N | 1 |
| Yang, J | 1 |
| Chrysis, D | 1 |
| Efthymiadou, A | 1 |
| Mermigka, A | 1 |
| Kritikou, D | 1 |
| Spiliotis, BE | 1 |
| Du, MR | 1 |
| Ju, GX | 1 |
| Li, NS | 1 |
| Jiang, JL | 1 |
| Yamagishi, S | 1 |
| Ueda, S | 1 |
| Nakamura, K | 1 |
| Matsui, T | 1 |
| Okuda, S | 1 |
| Sibal, L | 1 |
| Agarwal, SC | 1 |
| Home, PD | 1 |
| Vasan, RS | 1 |
| Marcovecchio, ML | 1 |
| Widmer, B | 1 |
| Turner, C | 1 |
| Dunger, DB | 1 |
| Dalton, RN | 1 |
| Salum, E | 1 |
| Kampus, P | 1 |
| Zilmer, M | 1 |
| Eha, J | 1 |
| Butlin, M | 1 |
| Avolio, AP | 1 |
| Põdramägi, T | 1 |
| Arend, A | 1 |
| Aunapuu, M | 1 |
| Kals, J | 1 |
| Päivä, H | 1 |
| Lehtimäki, T | 1 |
| Laakso, J | 1 |
| Ruokonen, I | 1 |
| Rantalaiho, V | 1 |
| Wirta, O | 1 |
| Pasternack, A | 1 |
| Laaksonen, R | 1 |
| Kawata, T | 1 |
| Daimon, M | 1 |
| Hasegawa, R | 1 |
| Teramoto, K | 1 |
| Toyoda, T | 1 |
| Sekine, T | 1 |
| Yamamoto, K | 1 |
| Uchida, D | 1 |
| Himi, T | 1 |
| Yoshida, K | 1 |
| Komuro, I | 1 |
| Yasuda, S | 1 |
| Miyazaki, S | 1 |
| Kanda, M | 1 |
| Goto, Y | 1 |
| Suzuki, M | 1 |
| Harano, Y | 1 |
| Nonogi, H | 1 |
| Ding, H | 1 |
| Triggle, CR | 1 |
| Devangelio, E | 1 |
| Santilli, F | 1 |
| Formoso, G | 1 |
| Ferroni, P | 1 |
| Bucciarelli, L | 1 |
| Michetti, N | 1 |
| Clissa, C | 1 |
| Ciabattoni, G | 1 |
| Consoli, A | 1 |
| Davì, G | 1 |
| Pleiner, J | 1 |
| Mittermayer, F | 1 |
| Langenberger, H | 1 |
| Winzer, C | 1 |
| Schaller, G | 1 |
| Pacini, G | 1 |
| Kautzky-Willer, A | 1 |
| Tura, A | 1 |
| Wolzt, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Dexamethasone Implant on Retinal Nerve Fiber and Optic Disc Morphology in Patients With Diabetic Maculopathy[NCT03927118] | 43 participants (Actual) | Observational | 2018-02-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for n(g),n(g')-dimethyl-l-arginine and Diabetic Angiopathies
| Article | Year |
|---|---|
Role of ADMA in the pathogenesis of microvascular complications in type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Retinopathy; Huma | 2023 |
Relationship between Serum Asymmetric Dimethylarginine Level and Microvascular Complications in Diabetes Mellitus: A Meta-Analysis.
Topics: Arginine; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; D | 2019 |
Role of Asymmetrical Dimethylarginine in Diabetic Microvascular Complications.
Topics: Animals; Arginine; Biomarkers; Diabetes Mellitus; Diabetic Angiopathies; Enzyme Inhibitors; Humans; | 2016 |
Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications.
Topics: Amidohydrolases; Animals; Arginine; Diabetic Angiopathies; Humans; Nitric Oxide Synthase; Risk Facto | 2008 |
Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus.
Topics: Arginine; Diabetic Angiopathies; Endothelium, Vascular; Humans | 2010 |
Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium.
Topics: Arginine; Biological Factors; Biomarkers; C-Reactive Protein; Cell Differentiation; Cell Proliferati | 2005 |
1 trial available for n(g),n(g')-dimethyl-l-arginine and Diabetic Angiopathies
| Article | Year |
|---|---|
Differential associations of circulating asymmetric dimethylarginine and cell adhesion molecules with metformin use in patients with type 2 diabetes mellitus and stable coronary artery disease.
Topics: Aged; Aged, 80 and over; Arginine; Cell Adhesion Molecules; Coronary Artery Disease; Diabetes Mellit | 2015 |
15 other studies available for n(g),n(g')-dimethyl-l-arginine and Diabetic Angiopathies
| Article | Year |
|---|---|
Lack of evidence of the correlation between plasma Asymmetrical Dimethylarginine correlation and IMT in type 2 diabetic patients with chronic vascular complication.
Topics: Adult; Aged; Arginine; Atherosclerosis; Carotid Artery, Internal; Carotid Intima-Media Thickness; Ca | 2021 |
Genetic and environmental determinants of dimethylarginines and association with cardiovascular disease in patients with type 2 diabetes.
Topics: Aged; Arginine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Environme | 2014 |
Relation of asymmetric dimethylarginine levels to macrovascular disease and inflammation markers in type 2 diabetic patients.
Topics: Aged; Arginine; Atherosclerosis; Biomarkers; Blood Sedimentation; C-Reactive Protein; Carotid Intima | 2014 |
Glycated peptides are associated with the variability of endothelial dysfunction in the cerebral vessels and the kidney in type 2 diabetes mellitus patients: a cross-sectional study.
Topics: Aged; Albuminuria; Arginine; Biomarkers; Breath Holding; Cohort Studies; Cross-Sectional Studies; Di | 2015 |
Asymmetric dimethylarginine is negatively correlated with hyperglycemia in children.
Topics: Adolescent; Arginine; Biomarkers; Body Mass Index; Cardiovascular Diseases; Child; Cross-Sectional S | 2015 |
ADMA: a specific biomarker for pathologic progress in diabetic microvascular complications?
Topics: Adult; Aged; Area Under Curve; Arginine; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2 | 2016 |
Osteoprotegerin, RANKL, ADMA, and Fetuin-A serum levels in children with type I diabetes mellitus.
Topics: Adolescent; alpha-2-HS-Glycoprotein; Arginine; Biomarkers; Cardiovascular Diseases; Child; Cohort St | 2017 |
A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuria.
Topics: Adolescent; Adult; Albuminuria; Arginine; Biomarkers; Brachial Artery; Case-Control Studies; Cell Ad | 2009 |
Asymmetric dimethylarginine in young people with Type 1 diabetes: a paradoxical association with HbA(1c).
Topics: Adolescent; Albuminuria; Arginine; Biomarkers; Blood Glucose; Cardiovascular Diseases; Child; Diabet | 2011 |
Effect of vitamin D on aortic remodeling in streptozotocin-induced diabetes.
Topics: Animals; Aorta, Thoracic; Aortic Diseases; Arginine; Biomarkers; Blood Pressure; Cholecalciferol; Di | 2012 |
Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy.
Topics: Aged; Arginine; Blood Glucose; Blood Pressure; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Typ | 2003 |
Serum asymmetric dimethylarginine as a marker of coronary microcirculation in patients with non-insulin dependent diabetes mellitus: correlation with coronary flow reserve.
Topics: Aged; Arginine; Biomarkers; Blood Flow Velocity; Coronary Artery Disease; Coronary Circulation; Diab | 2005 |
Intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synt
Topics: Arginine; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Female; Humans; H | 2006 |
Soluble RAGE in type 2 diabetes: association with oxidative stress.
Topics: Arginine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dinoprost; Enzy | 2007 |
Impaired vascular nitric oxide bioactivity in women with previous gestational diabetes.
Topics: Adult; Arginine; Body Mass Index; Diabetes Mellitus, Type 2; Diabetes, Gestational; Diabetic Angiopa | 2007 |